human recombinant vegf c (R&D Systems)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Name:

Recombinant Human VEGF Ax Protein

Description:

The Recombinant Human VEGF Ax Protein from R D Systems is derived from CHO The Recombinant Human VEGF Ax Protein has been validated for the following applications Bioactivity

Catalog Number:

9018-VE-025

Price:

329

Category:

Proteins and Enzymes

Source:

CHO-derived Recombinant Human VEGF-Ax Protein

Applications:

Bioactivity

Purity:

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining.

Conjugate:

Unconjugated

Size:

25 ug

Buy from Supplier

Structured Review

R&D Systems human recombinant vegf c
NIR fluorescent images of <t>VEGF-C</t> (n = 11) or PBS (n = 5) treated mice prior to and 2, 6, and 10 days after surgical removal of the left ALN. Double arrow, ICG injection site. Arrow head, ILN. Open arrow, internodal collecting lymphatic vessels. Asterisk, aberrant lymphatic drainage to the contralateral ALN. Double arrows, ICG injection site.

NIR fluorescent images of <t>VEGF-C</t> (n = 11) or PBS (n = 5) treated mice prior to and 2, 6, and 10 days after surgical removal of the left ALN. Double arrow, ICG injection site. Arrow head, ILN. Open arrow, internodal collecting lymphatic vessels. Asterisk, aberrant lymphatic drainage to the contralateral ALN. Double arrows, ICG injection site.

The Recombinant Human VEGF Ax Protein from R D Systems is derived from CHO The Recombinant Human VEGF Ax Protein has been validated for the following applications Bioactivity
https://www.bioz.com/result/human recombinant vegf c/product/R&D Systems
Average 93 stars, based on 1 article reviews
Price from $9.99 to $1999.99

human recombinant vegf c - by Bioz Stars, 2021-04

93/100 stars

Images

1) Product Images from "Characterization of internodal collecting lymphatic vessel function after surgical removal of an axillary lymph node in mice"

Article Title: Characterization of internodal collecting lymphatic vessel function after surgical removal of an axillary lymph node in mice

Journal: Biomedical Optics Express

doi: 10.1364/BOE.7.001100

NIR fluorescent images of VEGF-C (n = 11) or PBS (n = 5) treated mice prior to and 2, 6, and 10 days after surgical removal of the left ALN. Double arrow, ICG injection site. Arrow head, ILN. Open arrow, internodal collecting lymphatic vessels. Asterisk, aberrant lymphatic drainage to the contralateral ALN. Double arrows, ICG injection site.

Figure Legend Snippet: NIR fluorescent images of VEGF-C (n = 11) or PBS (n = 5) treated mice prior to and 2, 6, and 10 days after surgical removal of the left ALN. Double arrow, ICG injection site. Arrow head, ILN. Open arrow, internodal collecting lymphatic vessels. Asterisk, aberrant lymphatic drainage to the contralateral ALN. Double arrows, ICG injection site.

Techniques Used: Mouse Assay, Injection

Recombinant:

Article Title: Endothelial NO Synthase-Dependent S-Nitrosylation of β-Catenin Prevents Its Association with TCF4 and Inhibits Proliferation of Endothelial Cells Stimulated by Wnt3a
Article Snippet: The following primary antibodies were used: anti-myc-tag (9B11), anti-β-actin (8H10D10), and anti-BrdU (Bu20a) monoclonal antibodies (MAb) from Cell Signaling; anti-β-catenin, anti-eNOS, and anti-annexin II MAb from BD Transduction Laboratories; anti-TCF-4 (6H5-3) MAb from Upstate; and anti-Flag (M2) MAb from Sigma. .. Recombinant human VEGF-A (referred to as VEGF here), obtained from R & D Systems, was used for cell stimulation throughout this study. .. GSNO was from Sigma-Aldrich, and NOC-18 was from Santa Cruz.

Article Title: Control of Angiogenesis by Galectins Involves the Release of Platelet-Derived Proangiogenic Factors
Article Snippet: MTT [3-(4,5-dimethylthiaxol-2-yl)-2,5-diphaenyltetrazolium bromide] was from Promega Corporation (Madison, WI, USA). .. Recombinant VEGF-A, goat anti human VEGFR2/KDR/Flk-1, mouse anti human VEGF-A neutralizing antibody, and the corresponding irrelevant IgGs were purchased from R & D Systems (Minneapolis, MN, USA). .. Rabbit anti-human EGF neutralizing antibody and control IgG were obtained from Cell Signaling Technology (Danvers, MA, USA).

Article Title: Simultaneous in vivo imaging of blood and lymphatic vessel growth in Prox1-GFP/Flk1::myr-mCherry mice
Article Snippet: .. Pellets contained 10% (w/v) sulfcralfate (Sigma-Aldrich, St. Louis, MO), 12% (w/v) poly-hydroxyethylmethacrylate (HEMA; Sigma-Aldrich) dissolved in absolute ethanol, and recombinant human VEGF-A (R & D Systems, Minneapolis, MN), bFGF, or PBS. ..

Article Title: Attenuation of Choroidal Neovascularization by Histone Deacetylase Inhibitor
Article Snippet: Cells were harvested and lysed by RIPA buffer (Cell Signaling, Danvers, MA), and proteins were resolved on 4–15% Tris-HCl polyacrylamide gels (Bio-Rad) at 120 V. The proteins were transferred to polyvinylidene blotting membrane (Millipore, Bedford, MA). .. To assay HIF-1α, VEGF and PEDF, RPE cells that had been pre-exposed to TSA for 18 h were treated with CoCl2 for 6 h. To assay-pAkt, p-p42/44 and caspase 3, BCECs were treated with TSA for 24 h. To assay p-VEGFR2, HUVECs were treated with TSA for 48 h and then stimulated with 25 ng/mL human recombinant VEGF for 10 min. To assay VEGFR2, BCECs were treated with TSA for 24 h; HUVECs were treated with TSA for 48 h. The membranes were probed with the corresponding antibodies, as listed in Tables , and . .. Membranes were washed with TBS-Tween 20 (0.1%) (Bio-Rad) and then incubated with a horseradish peroxidase-conjugated secondary antibody (Vector Laboratories, Inc. Burlingame, CA) for 30 min at room temperature.

Article Title: Inhibition of VEGF and Angiopoietin-2 to Reduce Brain Metastases of Breast Cancer Burden
Article Snippet: .. Cells were incubated with DMEM (supplemented with 1% FBS) containing various concentrations of Ang-2 (recombinant human Angiopoietin-2, R & D Systems), VEGF (recombinant human VEGF, R & D Systems), L1-10 (Amgen), and/or bevacizumab (AvastinTM Genentech) at 37°C. ..

Article Title: PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling
Article Snippet: The enhanced chemiluminescence detection kit was from GE Healthcare (Little Chalfont, UK). .. Recombinant human VEGF-A was purchased from R & D Systems (Minneapolis, MN, USA). .. All materials for immunoblotting were purchased from Bio-Rad (Hercules, CA, USA).

Article Title: Vascular adaptation to a dysfunctional endothelium as a consequence of Shb deficiency
Article Snippet: Endothelial cell junctions were injected with conjugated CD31-antibody as above. .. Recombinant human VEGF-A (hrVEGF-A, R & D Systems) (1 ng) in 50 μl phosphate-buffered saline (PBS) was injected intra-arterially—leading to direct and efficient delivery to the left cremaster muscle. .. Quantification of VE-cadherin localization to adherens junctions was done as follows: grids were placed over VE-cadherin stained venules and the percentage cross points detected over non-stained venular area was counted manually and calculated in percent of total venular area.

Article Title: Real-time analysis of the binding of fluorescent VEGF165a to VEGFR2 in living cells: Effect of receptor tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes
Article Snippet: This tetramethyl-rhodamine (TMR) labeled VEGF (VEGF165 a-TMR) has been used in conjunction with VEGFR2 genetically fused to NanoLuc to provide detailed quantitative information on ligand binding characteristics, the effect of receptor tyrosine kinase inhibitors and the internalization of agonist-receptor complexes in living cells. .. 2.1 Materials All recombinant human VEGF ligand isoforms were purchased from R & D Systems (Abingdon, UK). .. Cediranib, pazopanib, sorafenib and vandetanib were supplied by Sequoia Research Products (Pangbourne, UK).

Cell Stimulation:

Incubation:

Injection:

Similar Products

vegf d (R&D Systems)

R&D Systems vegf d

Measurement of the specificity of TTAC-0001. ( a ) Binding of TTAC-0001 to VEGF isoforms. Black bar represents VEGF-165. Gray bar represents VEGF-C and blank bar represents <t>VEGF-D.</t> hIgG and bevacizumab were used as controls. ( b ) Specificity measurement of TTAC-0001 on VEGFRs by Biacore. Line, hVEGFR1-Fc coated chip; dashed line (–), hVEGFR2-Fc coated chip; dashed line (—), hVEGFR-3-Fc coated chip. 50 nM of TTAC-0001 was injected at a flow rate of 30 μl/min. ( c ) Inhibition of TTAC-0001 in binding VEGF isoforms to VEGFR-2. Closed rectangular represents <t>VEGF165.</t> Closed circle represents VEGF-C and Open circle represents VEGF-D. ( d ) Immunohistochemistry showed positive staining of TTAC-0001 in endothelial cells of mouse aorta and mouse brain bEND.3 cells from Balb/c mice. HUVECs and human GBM tumor tissues were used as controls. Triangle represents stained regions of each cell.

Vegf D, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vegf d/product/R&D Systems
Average 93 stars, based on 1 article reviews
Price from $9.99 to $1999.99

vegf d - by Bioz Stars, 2021-04

93/100 stars

Buy from Supplier

recombinant human vegf a (R&D Systems)

R&D Systems recombinant human vegf a

MDK inhibits <t>VEGF-A-mediated</t> VEGFR-2, AKT, and mitogen-activated protein kinase phosphorylation in HMVECs. Serumstarved HMVECs, plated on collagen I-coated plates, were either stimulated with VEGF-A (20 ng/ml) and MDK (10µg/ml) or pretreated with

Recombinant Human Vegf A, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human vegf a/product/R&D Systems
Average 94 stars, based on 1 article reviews
Price from $9.99 to $1999.99

recombinant human vegf a - by Bioz Stars, 2021-04

94/100 stars

Buy from Supplier

human vegf (R&D Systems)

R&D Systems human vegf

Significant positive correlations between the vitreous fluid levels of S100A4 and the levels of OPN (panel A ), soluble <t>syndecan-1</t> (panel B ), and <t>VEGF</t> (panel C ), as well as between the vitreous fluid levels of OPN and the levels of soluble syndecan-1 (panel D ) and VEGF (panel E ).

Human Vegf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human vegf/product/R&D Systems
Average 95 stars, based on 1 article reviews
Price from $9.99 to $1999.99

human vegf - by Bioz Stars, 2021-04

95/100 stars

Buy from Supplier

Human VEGF C Antibody (R&D Systems)

N/A

The Human VEGF C Antibody from R D Systems is a goat polyclonal antibody to VEGF C This antibody reacts with human The Human VEGF C Antibody has been validated

Buy from Supplier

Image Search Results

Journal: mAbs

Article Title: TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis

doi: 10.1080/19420862.2015.1045168

Figure Lengend Snippet: Measurement of the specificity of TTAC-0001. ( a ) Binding of TTAC-0001 to VEGF isoforms. Black bar represents VEGF-165. Gray bar represents VEGF-C and blank bar represents VEGF-D. hIgG and bevacizumab were used as controls. ( b ) Specificity measurement of TTAC-0001 on VEGFRs by Biacore. Line, hVEGFR1-Fc coated chip; dashed line (–), hVEGFR2-Fc coated chip; dashed line (—), hVEGFR-3-Fc coated chip. 50 nM of TTAC-0001 was injected at a flow rate of 30 μl/min. ( c ) Inhibition of TTAC-0001 in binding VEGF isoforms to VEGFR-2. Closed rectangular represents VEGF165. Closed circle represents VEGF-C and Open circle represents VEGF-D. ( d ) Immunohistochemistry showed positive staining of TTAC-0001 in endothelial cells of mouse aorta and mouse brain bEND.3 cells from Balb/c mice. HUVECs and human GBM tumor tissues were used as controls. Triangle represents stained regions of each cell.

Article Snippet: Recombinant human VEGF121, VEGF165, VEGF-C, VEGF-D and KDR (ECD1–7)-Fc were also purchased from R & D systems.

Techniques: Binding Assay, Chromatin Immunoprecipitation, Injection, Flow Cytometry, Inhibition, Immunohistochemistry, Staining, Mouse Assay

MDK inhibits VEGF-A-mediated VEGFR-2, AKT, and mitogen-activated protein kinase phosphorylation in HMVECs. Serumstarved HMVECs, plated on collagen I-coated plates, were either stimulated with VEGF-A (20 ng/ml) and MDK (10µg/ml) or pretreated with

Journal:

Article Title: The Growth Factor Midkine Antagonizes VEGF Signaling In Vitro and In Vivo 1

doi:

Figure Lengend Snippet: MDK inhibits VEGF-A-mediated VEGFR-2, AKT, and mitogen-activated protein kinase phosphorylation in HMVECs. Serumstarved HMVECs, plated on collagen I-coated plates, were either stimulated with VEGF-A (20 ng/ml) and MDK (10µg/ml) or pretreated with

Article Snippet: Recombinant human VEGF-A, MDK, tissue inhibitor of metalloproteinase 2 (TIMP-2), bFGF, and human transforming growth factor alpha (TGF-α), tumor necrosis factor alpha (TNF-α), and TIMP-2 ELISA kits (HS Quantikine) were purchased from R & D Systems Inc. (Minneapolis, MN).

Techniques:

Midkine-induced upregulation of TIMP-2 and downregulation of TGF-α and TNF-α inhibits VEGF-A-mediated proliferation and BrdU incorporation of HMVECs. (A) Midkine suppresses the proliferation of ECs. Cell number was determined by the measurement

Journal:

Article Title: The Growth Factor Midkine Antagonizes VEGF Signaling In Vitro and In Vivo 1

doi:

Figure Lengend Snippet: Midkine-induced upregulation of TIMP-2 and downregulation of TGF-α and TNF-α inhibits VEGF-A-mediated proliferation and BrdU incorporation of HMVECs. (A) Midkine suppresses the proliferation of ECs. Cell number was determined by the measurement

Techniques: BrdU Incorporation Assay

MDK inhibits VEGF-A-induced neovascularization and vascular permeability in vivo . (A) The CAM assay was performed either with PBS, VEGF-A, MDK, or both growth factors (see Materials and Methods). This study was performed double-blinded, and effects on

Journal:

Article Title: The Growth Factor Midkine Antagonizes VEGF Signaling In Vitro and In Vivo 1

doi:

Figure Lengend Snippet: MDK inhibits VEGF-A-induced neovascularization and vascular permeability in vivo . (A) The CAM assay was performed either with PBS, VEGF-A, MDK, or both growth factors (see Materials and Methods). This study was performed double-blinded, and effects on

Techniques: Permeability, In Vivo, Chick Chorioallantoic Membrane Assay

Myocardin nitrosylated at Cys596 is required for STAT3 activation in VSMC phenotypic switch by VEGF-A. ( A ) Biotin switch analysis of T/G HA-VSMC cells transfected with Myc-tagged Myocardin and followed by treatment with 200 μM GSNO for 10 min or 100 ng/mL VEGF-A for 48 hours ( B ) Biotin switch analysis of T/G HA-VSMC cells transfected with a 100 pmol of VEGFR2 or STAT3 siRNA mixture and 2 μg of Myc-tagged Myocardin and subsequently treated with 100 ng/mL VEGF-A for 48 hours. ( C ) Western blot analysis of T/G HA-VSMC cells transfected with Myocardin-WT or Myocardin-ΔC and activated with 100 ng/mL VEGF-A for 48 hours. The phosphorylated STAT3 and total STAT3 protein was determined by Western blot analysis in the cell lysates. ( D ) Western blot analysis of ACTA2, SM22 and Myh11 protein level in T/G HA-VSMC cells transfected with Myocardin-WT or Myocardin-ΔC then treated with 100 ng/mL VEGF-A for 48 hours and quantified the western blot data by Quantity One software. β-actin is a loading control. ** p

Journal: Scientific Reports

Article Title: VEGF-A Stimulates STAT3 Activity via Nitrosylation of Myocardin to Regulate the Expression of Vascular Smooth Muscle Cell Differentiation Markers

doi: 10.1038/s41598-017-02907-6

Figure Lengend Snippet: Myocardin nitrosylated at Cys596 is required for STAT3 activation in VSMC phenotypic switch by VEGF-A. ( A ) Biotin switch analysis of T/G HA-VSMC cells transfected with Myc-tagged Myocardin and followed by treatment with 200 μM GSNO for 10 min or 100 ng/mL VEGF-A for 48 hours ( B ) Biotin switch analysis of T/G HA-VSMC cells transfected with a 100 pmol of VEGFR2 or STAT3 siRNA mixture and 2 μg of Myc-tagged Myocardin and subsequently treated with 100 ng/mL VEGF-A for 48 hours. ( C ) Western blot analysis of T/G HA-VSMC cells transfected with Myocardin-WT or Myocardin-ΔC and activated with 100 ng/mL VEGF-A for 48 hours. The phosphorylated STAT3 and total STAT3 protein was determined by Western blot analysis in the cell lysates. ( D ) Western blot analysis of ACTA2, SM22 and Myh11 protein level in T/G HA-VSMC cells transfected with Myocardin-WT or Myocardin-ΔC then treated with 100 ng/mL VEGF-A for 48 hours and quantified the western blot data by Quantity One software. β-actin is a loading control. ** p

Article Snippet: Reagents Recombinant human VEGF-A protein was obtained from R & D Systems and S-Nitrosoglutathione (GSNO) was obtained from santa cruz.

Techniques: Activation Assay, Transfection, Western Blot, Software

STAT3 acts as a downstream mediator for VEGFR2 activation induced by VEGF-A. ( A ) Western blot analysis of T/G HA-VSMC cells transfected with siRNAs for STAT1, STAT3, or STAT5 and treated with 100 ng/mL VEGF-A for 48 hours. ( B ) Western blot analysis of T/G HA-VSMC cells transfected with siRNAs for Myh11 and Smoothlin and quantified the western blot data by Quantity One software. β-actin is a loading control. ** p

Journal: Scientific Reports

Article Title: VEGF-A Stimulates STAT3 Activity via Nitrosylation of Myocardin to Regulate the Expression of Vascular Smooth Muscle Cell Differentiation Markers

doi: 10.1038/s41598-017-02907-6

Figure Lengend Snippet: STAT3 acts as a downstream mediator for VEGFR2 activation induced by VEGF-A. ( A ) Western blot analysis of T/G HA-VSMC cells transfected with siRNAs for STAT1, STAT3, or STAT5 and treated with 100 ng/mL VEGF-A for 48 hours. ( B ) Western blot analysis of T/G HA-VSMC cells transfected with siRNAs for Myh11 and Smoothlin and quantified the western blot data by Quantity One software. β-actin is a loading control. ** p

Article Snippet: Reagents Recombinant human VEGF-A protein was obtained from R & D Systems and S-Nitrosoglutathione (GSNO) was obtained from santa cruz.

Techniques: Activation Assay, Western Blot, Transfection, Software

Myocardin is nitrosylated by nitric oxide. ( A ) Western blot analysis to detect phosphorylated STAT3 and total STAT3 protein in T/G HA-VSMC cells pretreated with Na3VO4 (10, 100, and 500 μM) and then treated with 100 ng/mL VEGF-A for 48 hours. ( B ) Results of a biotin switch assay on HEK293T cells transfected with Myc-Myocardin and treated with the nitric oxide donor nitrosoglutathione (GSNO) (500 μM) for 10 min at room temperature. ( C ) Western blot analysis to detect phosphorylated STAT3 and total STAT3 protein in T/G HA-VSMC cells pretreated with GSNO (500 μM) for 10 min at room temperature and quantified the western blot data by Quantity One software. β-actin is a loading control. ** p

Journal: Scientific Reports

Article Title: VEGF-A Stimulates STAT3 Activity via Nitrosylation of Myocardin to Regulate the Expression of Vascular Smooth Muscle Cell Differentiation Markers

doi: 10.1038/s41598-017-02907-6

Figure Lengend Snippet: Myocardin is nitrosylated by nitric oxide. ( A ) Western blot analysis to detect phosphorylated STAT3 and total STAT3 protein in T/G HA-VSMC cells pretreated with Na3VO4 (10, 100, and 500 μM) and then treated with 100 ng/mL VEGF-A for 48 hours. ( B ) Results of a biotin switch assay on HEK293T cells transfected with Myc-Myocardin and treated with the nitric oxide donor nitrosoglutathione (GSNO) (500 μM) for 10 min at room temperature. ( C ) Western blot analysis to detect phosphorylated STAT3 and total STAT3 protein in T/G HA-VSMC cells pretreated with GSNO (500 μM) for 10 min at room temperature and quantified the western blot data by Quantity One software. β-actin is a loading control. ** p

Article Snippet: Reagents Recombinant human VEGF-A protein was obtained from R & D Systems and S-Nitrosoglutathione (GSNO) was obtained from santa cruz.

Techniques: Western Blot, Biotin Switch Assay, Transfection, Software

Significant positive correlations between the vitreous fluid levels of S100A4 and the levels of OPN (panel A ), soluble syndecan-1 (panel B ), and VEGF (panel C ), as well as between the vitreous fluid levels of OPN and the levels of soluble syndecan-1 (panel D ) and VEGF (panel E ).

Journal: Molecular Vision

Article Title: S100A4 is upregulated in proliferative diabetic retinopathy and correlates with markers of angiogenesis and fibrogenesis

doi:

Figure Lengend Snippet: Significant positive correlations between the vitreous fluid levels of S100A4 and the levels of OPN (panel A ), soluble syndecan-1 (panel B ), and VEGF (panel C ), as well as between the vitreous fluid levels of OPN and the levels of soluble syndecan-1 (panel D ) and VEGF (panel E ).

Article Snippet: ELISA kits for human VEGF (Cat No: SVE00), human syndecan-1 (Cat No: DY2780), and human OPN (Cat No: DY1433) were purchased from R & D Systems.

Techniques:

Detectable levels of S100A4 (panel A ), osteopontin (OPN; panel B ), soluble syndecan-1 (panel C ), and vascular endothelial growth factor (VEGF; panel D ) in vitreous samples from eyes with proliferative diabetic retinopathy (PDR) and rhegmatogenous retinal detachment (RD). The dashed line represents the detection limit (9 pg/ml) of the assay for VEGF (panel D ). The mean levels are indicated by horizontal solid lines.

Journal: Molecular Vision

Article Title: S100A4 is upregulated in proliferative diabetic retinopathy and correlates with markers of angiogenesis and fibrogenesis

doi:

Figure Lengend Snippet: Detectable levels of S100A4 (panel A ), osteopontin (OPN; panel B ), soluble syndecan-1 (panel C ), and vascular endothelial growth factor (VEGF; panel D ) in vitreous samples from eyes with proliferative diabetic retinopathy (PDR) and rhegmatogenous retinal detachment (RD). The dashed line represents the detection limit (9 pg/ml) of the assay for VEGF (panel D ). The mean levels are indicated by horizontal solid lines.

Article Snippet: ELISA kits for human VEGF (Cat No: SVE00), human syndecan-1 (Cat No: DY2780), and human OPN (Cat No: DY1433) were purchased from R & D Systems.

Techniques:

Structured Review

Images

1) Product Images from "Characterization of internodal collecting lymphatic vessel function after surgical removal of an axillary lymph node in mice"

Related Articles

Recombinant:

Cell Stimulation:

Incubation:

Injection:

Similar Products

Image Search Results